|
Hungary Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Hungary Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Hungary .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Hungarian pharmaceutical and healthcare industry.
Competitive intelligence, Hungarian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Hungarian market.
The Hungary Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Hungary Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Hungarian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Hungary to test other views – a key input for successful budgeting and strategic business planning in the Hungarian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Hungarian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hungary .
- Exploit The Latest Competitive Hungarian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Hungary .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Hungary Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Hungary Pharmaceuticals And Healthcare Industry SWOT |
| Hungary Political SWOT |
| Hungary Economic SWOT |
| Hungary Business Environment SWOT |
Chapter - Pharmaceuticals & Healthcare Business Environment |
| Table: Central And Eastern Europe Pharmaceuticals Business Environment Ratings For Q209 |
| Limits to Potential Returns |
Chapter - Hungary – Market Summary |
| Regulatory Regime |
| Recent EU Regulatory Developments |
| Intellectual Property Regime |
Chapter - Pricing Regime |
| Table: Hungary – Pharmaceutical Price Build-Up |
| Table: Hungary – Average Pharmacy Mark-Up |
Chapter - Reimbursement Regime |
| Price Cuts |
| Pricing and Reimbursement Reforms |
Chapter - Industry Developments |
| Epidemiology |
| Table: Disease Burden In CEE |
Chapter - Healthcare Financing |
| Healthcare Reforms |
| Hospital Sector Reforms |
| Research and Development |
| Table: Special Incentive Package For Investors Willing To Establish An R&D Facility Worth At Least EUR10mn in Hungary |
| Biotechnology Sector |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Hungary's Drug Market Forecast, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Hungary's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Hungary- Economic Activity |
| Prescription Market Forecast |
| Table: Hungary's Prescription Market Indicators, 2004-2013 (HUFmn unless otherwise) stated) |
| OTC Market Forecast |
| Table: Hungary's OTC Market Indicators, 2004-2013 (HUFmn unless otherwise) stated) |
| Patented Market Forecast |
| Table: Hungary's Patented Drug Market Indicators, 2004-2013 |
| Generics Market Forecast |
| Table: Hungary's Generics Market Indicator Forecasts, 2004-2013 |
| Export/Import Forecasts |
| Table: Hungary's Import/Export Market Forecasts, 2004-2013 (US$mn) |
| Medical Devices Forecast |
| Table: Hungary's Medical Device Market 2004-2013 |
| Other Healthcare Data Forecasts |
| Table: Hungary's Other Healthcare Data, 2004-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Leading Pharmaceutical Companies By Ownership |
| Domestic Price Cuts Calculated For Total Egis Portfolio |
| Wholesale and Retail Pharmacy Sector |
Chapter - Company Monitor |
| Multinational Companies |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Merck & Co |
| Eli Lilly |
| Krka |
| Domestic Manufacturers |
| Gedeon Richter |
| Egis Pharmaceuticals (Servier) |
Chapter - Country Snapshot: Hungary Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
Chapter - Sources |
|
Hungary Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Hungary’s recent history of slashing pharmaceutical prices, restricting reimbursement and squeezing manufacturers has made the market an increasingly unattractive proposition for multinational pharmaceutical companies. Following consistent market growth up to 2006, restrictive regulatory modifications have reduced market spending in the last two years. Over the next five years BMI forecasts the compound annual growth rate (CAGR) for Hungarian drug expenditure will be -0.23%, with spending restrictions weighted towards the front end of the forecast period.
Limited optimism for market growth is one of the key reasons for Hungary’s slip to 10th position in BMI’s Pharmaceuticals & Healthcare Business Environment Rankings for Q209. Despite a reasonable absolute size, the country has a negative outlook for growth, combined with a constrictive regulatory environment – including the ‘claw-back’ and medical representative taxes – and below average country risk scores.
Hungary’s pharmaceutical budget is set to face further downward pressure in 2009 as a result of the worst recession since the country’s 1991 transition to market capitalism. In Q109 the government announced that healthcare spending would be cut by HUF30bn (US$135mn), with half the savings coming from the National Health Insurance Fund (OEP)’s drug subsidies budget. In addition price increases – as a result of a weakened forint – are expected in April 2009. BMI believes the cuts will not only burden pharmaceutical companies but provide further impetus for them to reduce their presence in Hungary.
Negative currency fluctuations have also impacted manufacturers, who have called for price adjustments during Q209. In 2008 786 drugs were reduced by an average of 15%. Despite a further 4% reduction for 355 drugs in January 2009, increases across 2009 may be inevitable as a response to the devalued forint.
Domestic manufacturers Gedeon Richter and Egis have demonstrated the ongoing struggles for pharmaceutical companies over the last year. Recent financial results show domestic sales contraction, while the current economic downturn has compounded issues. Richter has announced it will not publish forecasts for 2009 due to the volatile economic environment. The CEO, Erik Bogsch, stated that while the company’s Q408 results do not reflect the ongoing crisis, 2009 will prove to be a difficult year for the pharmaceutical sector. Both companies continue to look to foreign markets as the prime opportunity for growth.
|
Hungary Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |